Literature DB >> 15767829

Developmental phases of inflammation-induced massive lymphoid hyperplasia and extensive changes in epithelium in an experimental model of allergy: implications for a direct link between inflammation and carcinogenesis.

Mahin Khatami1.   

Abstract

Direct evidence that inflammation is linked to carcinogenesis has yet to be established. Very few data are available on the developmental phases of inflammation-induced immune dysfunction that may lead to tumorigenesis. In a series of studies conducted in the 1980s and 1990s, an experimental model of acute and chronic inflammation was established in guinea pig conjunctiva by topical application of fluoresceinyl ovalbumin (FLOA) for up to 30 months. In this updated report, some of the findings are reanalyzed and expanded to identify that at lease 3 developmental phases were involved during the entire course of inflammatory responses including (1) an acute response (phase A) involving IgE-mast cell sensitization and degranulation; (2) an intermediate phase (phase B), a desensitization phenomenon and loss of mast cell function and neovascularization; (3) a chronic response (phase C) and induction of massive lymphoid hyperplasia, follicular formation with germinal centers, increased swollen goblet cells, extensive epithelial thickening and thinning, and angiogenesis. The results suggest evidence of a direct association between inflammation and the development of tumor-like lesions in lymphoid tissues and extensive changes in adjacent epithelia. Confirmation that inflammation induces irreversible changes in lymphoid and epithelial tissues leading to lymphoid tumorigenesis and/or carcinogenesis requires further studies. Understanding the developmental phases of immune dysfunction may provide unique opportunities for diagnosis and treatment of inflammatory diseases, autoimmune disorders, and cancers including lymphomas associated with Sjogren syndrome, squamous cell carcinoma of the conjunctiva, and other lymphomas or epithelial cancers. It is suggested that inflammatory mediators are ideal targets (biomarkers) for diagnosis, chemoprevention, and therapy for several cancers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15767829     DOI: 10.1097/01.mjt.0000143699.91156.21

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  8 in total

1.  Erlotinib protects against LPS-induced endotoxicity because TLR4 needs EGFR to signal.

Authors:  Sarmishtha De; Hao Zhou; David DeSantis; Colleen M Croniger; Xiaoxia Li; George R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-20       Impact factor: 11.205

2.  Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis.

Authors:  Salomé González-Reyes; Laura Marín; Lucía González; Luis O González; José M del Casar; Maria L Lamelas; José M González-Quintana; Francisco J Vizoso
Journal:  BMC Cancer       Date:  2010-12-03       Impact factor: 4.430

3.  Benign Lymphoid Hyperplasia Presenting as Bilateral Scleral Nodules.

Authors:  Ricardo J Cumba; Rene Vazquez-Botet
Journal:  Case Rep Ophthalmol Med       Date:  2015-09-01

4.  Is cancer a severe delayed hypersensitivity reaction and histamine a blueprint?

Authors:  Mahin Khatami
Journal:  Clin Transl Med       Date:  2016-08-23

Review 5.  Deceptology in cancer and vaccine sciences: Seeds of immune destruction-mini electric shocks in mitochondria: Neuroplasticity-electrobiology of response profiles and increased induced diseases in four generations - A hypothesis.

Authors:  Mahin Khatami
Journal:  Clin Transl Med       Date:  2020-12

6.  Chronic Inflammation: Synergistic Interactions of Recruiting Macrophages (TAMs) and Eosinophils (Eos) with Host Mast Cells (MCs) and Tumorigenesis in CALTs. M-CSF, Suitable Biomarker for Cancer Diagnosis!

Authors:  Mahin Khatami
Journal:  Cancers (Basel)       Date:  2014-01-27       Impact factor: 6.639

7.  Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs.

Authors:  Hiroshi Maeda; Mahin Khatami
Journal:  Clin Transl Med       Date:  2018-03-01

8.  Cancer; an induced disease of twentieth century! Induction of tolerance, increased entropy and 'Dark Energy': loss of biorhythms (Anabolism v. Catabolism).

Authors:  Mahin Khatami
Journal:  Clin Transl Med       Date:  2018-07-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.